ABSTRACT. Objectives: To estimate the annual rate of change scores (ARC) on the Mini-Mental State Examination (MMSE) in Alzheimer's disease (AD) and to identify study or population characteristics that may affect the ARC estimation. Methods: MEDLINE was searched for articles published from January 1981 to November 1997 using the following keywords: AD and longitudinal study or prognosis or cognitive decline. The bibliographies of review articles and relevant papers were searched for additional references. All retrieved articles were screened to meet the following inclusion criteria: (a) original study; (b) addressed cognitive decline or prognosis or course of AD; (c) published inEnglish; (d) study populationincluded ADpatients withascertainable sample size; (e) used either clinical or pathological diagnostic criteria; (f) longitudinal study design; and (g) used the MMSE as one of the outcome measures. Data were systematically abstracted from the included studies, and a random effects regression model was employed to synthesize relevant data across studies and to evaluate the effects of study methodology on ARC estimation and its effect size. Results: Of the 439 studies screened, 43 met all the inclusion criteria.
Progressive cognitive decline is a cardinal feature of Alzheimer's disease (AD) and an essential criterion for establishing the clinical diagnosis of the disorder (American Psychiatric Association, 1987; McKhann et al., 1984) . Knowledge of the rate of cognitive decline in AD is fundamental to understanding the natural history of the disorder, planning patient care, allotting medical and social resources, and evaluating the effectiveness of clinical interventions (Galasko et al., 1991; .
During the past decade, longitudinal studies measuring cognitive decline in AD patients have proliferated (Galasko et al., 1991; . These studies have provided information on the rate of cognitive decline in AD patients as measured by annual rate of change scores (ARC) on mental status examinations or global cognitive tests. Unfortunately, there has been great variability in the ARC estimates across studies. Because these studies differed in the selection and diagnosis of AD patients, choice of instruments, follow-up length, number of assessments, and statistical methods, it is difficult to determine whether the observed variability reflects true heterogeneity of AD course, methodological differences, or both. Thus, we decided to conduct a meta-analysis of ARC by systematically reviewing studies addressing cognitive decline in AD using the Mini-Mental State Examination (MMSE; Folstein et al., 1975) , and we identify methodological characteristics of studies or differences in patient populations that might have contributed to the observed variability in the ARC.
METHODS
The review process, modified from the one described by Oxman and colleagues (1994) , involved systematic selection of articles, abstraction of data, descriptive presentation of the characteristics of studies, and quantitative synthesis of the results using a random effect model (Cooper & Hedges, 1994) .
Selection of Articles
To locate relevant studies, we first searched MEDLINE for studies published from January 1981 to November 1997, using the keywords "Alzheimer's disease" and "longitudinal study'' or "prognosis" or "cognitive decline." Next, we searched the bibliographies of relevant papers and review articles for additional papers. Finally, the abstracts of all retrieved articles were screened by one of the authors (L. H.) to meet the following seven inclusion criteria: (a) original study; (b) addressed cognitive decline or prognosis or course of AD; (c) published in English; (d) study population included AD patients with ascertainable sample size; (e) used either clinical or pathological diagnostic criteria; (f) longitudinal study design; and (g) used the MMSE as one of the outcome measures. If the study met all the inclusion criteria or a decision could not be made based on its abstract, the original paper was then retrieved. To avoid excluding relevant studies, a sample of 64 studies was independently evaluated by another author (M. C.). Interreviewer agreement on application of exclusion/inclusion criteria was satisfactory (kappa = .79 for 58 abstracts, and 1.0 for 6 papers). Subsequently, a
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list of all the included papers was sent to two experts for comment and suggestion for additional papers.
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When they were not provided, we calculated ARC by dividing the difference of baseline and endpoint mean scores of MMSE of the follow-up group with mean interval in year between the two times of assessments. To calculate SD of ARC, we used either the t or p value of the paired t test in the follow-up groups if they were available, or pooled SDs of baseline and endpoint MMSE scores of the follow-up groups as a conservative approximation.
Because methodology and population characteristics differed from study to study, we used a multiple random effects regression model to synthesize data and to evaluate the impact of study characteristics on ARC estimates. Such a random effects model would, according to Cooper and Hedges (1994) , allow for the true ARC to vary from study to study and for residual heterogeneity of ARC to be explained by a random error after taking into account known or suspected study characteristics. In addition, because the accuracy of the ARC estimates may also vary across studies, a weighted regression analysis was employed in which studies with high accuracy (i.e., low S D of ARC) were given more weight (Cooper & Hedges, 1994) .
The following variables were included as covariates in the model: mean age in years, years of education, age at onset, length of follow-up in months, number of assessments, and number of study centers involved. Because most studies reported the mean and/or minimum MMSE scores of subjects at entry, we used only the MMSE scores as indices of dementia severity at entry, though other severity measures might also have been used in some studies. Within each study population, we calculated the percentages
Abstraction of Data
One author (L. H.) used a standard form to abstract the following information from included studies: (a) Study features-research facilities and settings, sources and referral pattern of the patients, follow-up methods, diagnostic and inclusion criteria, length of followup, and number of assessments during follow-up; (b) Study population-number of subjects and subgroups, age, gender and education, age at onset, duration and severity of AD at entry; and ( c ) Study results-MMSE scores at baseline and during the follow-up period and corresponding standard deviations (SDs), estimated ARC, and its SD; in addition, test statistics, such as t or F, and p values were also retrieved for computing unavailable ARC estimate or its variance. When relevant data were presented by dividing the same patient group in different ways, we used only the data that were the most complete and in which subgroup sample sizes were the most equal. Abstracted data were checked for accuracy by two authors: M.C. for study and population characteristics and F. B. for study results.
Statistical Analysis
The major objective and one of the advantages of a quantitative meta-analysis is its ability to summarize results from many different studies. To synthesize the estimates of ARC across studies, we first tried to use the original values of ARC and its SD provided in the paper. of probable AD of female patients and of subjects who did not complete followup. We also created two categorical variables to denote the source of the ARC/ SD estimate (presented in the original paper, or calculated by us) and study design (retrospective, involved both retrospective and prospective components, or prospective). To avoid underestimating within-study variation of ARC, we treated subgroups of patients as an independent sample.
In addition to ARC, we ran the same analysis with the effect size (ES) of ARC, which is a ratio of ARC to its S D (Cooper & Hedges, 1994) . ES is frequently utilized for sample size calculation in clinical trials or for comparing outcome measures derived from different instruments. Based on the same rationale, we judged that ES might serve as an index of reliability or precision of ARC measure for each study. Indeed, a study with a large ARC may have a small ES if there is large variability associated with the ARC estimate as measured by the SD. Thus, modeling ES would provide additional information to our understandings of ARC variation in terms of the reliability or precision of the measurement.
We first evaluated each covariate individually in simple random effect regression models. Then we fitted a multiple random effect model by including all significant covariates (p < .05) in the one-covariate model. Following a backwards selection procedure, we reduced this multivariate model by deleting the least significant (i.e., highest p value greater than .05) covariate at a time, until all the covariates left in the model were statistically significant. Each covariate was evaluated in both continuous and categorical format. Categorization of continuous or proportional variables was made by using tertile or median values of the study population or clinically relevant criteria as cutoff points.
All the statistical analyses were conducted using SAS IML software, version 6.12 (SAS, 1997).
RESULTS
A total of 439 potentially relevant studies was identified by the aforementioned search strategy; based on the title and abstract, 142 were retrieved for more detailed evaluation. Of these, 99 were further excluded due to one or more of the following reasons: (a) not original study (n = 3); (b) not addressing cognitive decline or prognosis or course of AD (n = 38); (c) not published in English ( n = 2); (d) not including ascertainable AD patients ( n = 6); (e) not using established diagnostic criteria (n = 6); (f) not longitudinal design ( n = 6); or (8) not using the MMSE as a longitudinal outcome measure ( n = 78).
Forty-three studies that had met all the seven inclusion criteria were retrieved for this meta-analysis. Of these, 34 (79%) studies were conducted in the USA, especially in university-affiliated AD research centers. Thirty-eight (88%) were published between 1990 and 1997. Study designs included prospective cohort or clinical follow-up studies ( n = 37) or retrospective chart review ( n = 6). The most frequently used diagnostic criteria were NINCDS/ADRDA ( n = 37), followed by ICD-10 ( n = 2) (World Health Organization, 1992) and DSM-I11 (n = 1). Characteristics of study population and follow-up period varied greatly across the studies, but can be summarized as follows: mean age at entry ranged from 56 to 82 years (median: 72.5); percentage of female subjects ranged from 0 to 87.5% (median: 62%); mean education ranged from 8.7 to 16.5 years (median: 12.7); mean MMSE at entry ranged from 7.2 to 26 (median: 18.4); mean follow-up length ranged from 10 to 60 months (median: 21); and number of assessments ranged from 2 to 8 (median: 3).
Of the 43 included studies, 6 were not used for quantitative meta-analysis due to either lack of adequate data to compute S D of ARC (n = 2, data not shown) or potential overlapping of the study population with other included studies ( n = 4, data not shown). For the remaining 37 studies, which consisted of 65 subgroups of AD patients with a total sample size of 3,492, the main methodological and population characteristics, estimates of ARC, and estimates of ES are presented in Table 1 . Of the 37 studies, the ARC estimates ranged from 0.9 to 5.7 and the ES estimates from 0.3 to 6.0.
When fitting a simple random effect regression model on the ARCs with inclusion of a single covariate, none of the covariates was statistically significant (all p values were greater than .05, data not shown). Thus, final random effect model included an intercept and a random effect only. The estimate of the intercept was 3.3 (95% confidence interval [CI] , 2.9 to 3.7), corresponding to the pooled estimate of ARC across studies. The random effect was statistically greater than zero ( p < .OOOl), suggesting significant unexplained variability of ARCs across studies.
The modeling results of ES are presented in Table 2 . In the one-covariate models, the minimum MMSE at entry, proportion of female subjects, number of assessments, source of ARC/SD, length of follow-up, age at entry, and 235 age at onset were significantly related to ES. When running multiple regression analysis, started with simultaneous inclusion of all these significant covariates except for age at onset due to its small sample size, we ended up with a final model that included two significant covariates, minimum MMSE at entry (categorized into 55, 6-14, and 115) and number of assessments (categorized into 2, 3, and 4 or more) ( Table 2 ). The random effect was significantly greater than zero ( p < .OOOl), suggesting significant unexplained heterogeneity remaining.
DISCUSSION
Based on our review of the 37 longitudinal studies of AD published during the last 10 years, we estimated the average ARC to be 3.3 MMSE points (95% CI, 2.9-3.7). Because this meta-analysis was conducted in a large sample of published studies involving 3,492 AD patients followed over an average period of 2 years, our pooled ARC estimate provides a better approximation of population ARC: in AD patients than that from a single study. Given that use of the MMSE is almost universal in dementia clinics (Galasko et al., 1991; Tombaugh & McIntyre, 1992) , such an estimate provides clinicians with a guide to assess the deterioration of patients and counsel their families. In addition, this combined ARC estimate may be useful in assessing effects of interventions hypothesized to halt AD progression, and in evaluating the representativeness of the change over time of the placebo groups in clinical trials. Of course, we acknowledge the great variability in ARC measures across studies, as evidenced by the significant random effect term in the regression model. One of the objectives of this metaanalysis was to determine the underlying source(s) of observed heterogeneity of ARC estimates. Although none of the study characteristics we evaluated appeared to be significant in explaining the variability of ARC, we observed a positive correlation between ES of ARC with number of assessments and minimum MMSE score at entry. These results seem consistent with findings of previous studies that an increase in number of assessments or length of follow-up would improve the reliability of ARC estimates (Morris et al., 1993; Stern et al., 1992; van Belle et al., 1990) , or suggest that more number of assessments would increase the likelihood of observing a cognitive decline of AD patients.
On the other hand, the observed association between ES and baseline MMSE score may suggest that initial cognitive function would also affect the reliability of ARC measurements, in addition to predicting cognitive decline of AD patients, as reported by previous studies (Burns et al., 1991; Drachman et al., 1990; Haxby et al., 1992; Jacobs et al., 1994; Morris et al., 1993; Rich et al., 1995; Salmon et al., 1990; Teri et al., 1990) . Thus, to improve the reliability of ARC measurement and to facilitate comparisons of ARC estimates across studies, future studies should probably use stratumspecific ARCS by baseline cognitive function of patients, instead of an overall ARC, as indices of cognitive decline. Based on this meta-analysis and the popularity of the MMSE, we propose that the MMSE be used as a standard instrument for estimating stratum-specific ARC, as have several authors (Burns et al., 1991; Drachman et al., 1990; Ferris et al., 1997) and that uniform cutoff points be used to standardize such stratifica-tion procedure. However, what cutoff points should be used needs to be determined in light of both clinical significance and statistical justification.
Reasons that may underlie our failure to detect significant predictors of ARC variability include: 1. The covariates we studied may have no consistent effect on ARC and our results correctly reflect the heterogeneity of prognostic findings in AD patients. For example, a most intensively studied prognostic factor, initial severity of dementia, has been reported to predict faster decline (Burns et al., 1991; Drachman et al., 1990; Morris et al., 1993; Teri et al., 1990) or slower decline (Rich et al., 1995) or to have no effect (Goldblum et al., 1994; Jacobs et al., 1994; Salmon et al., 1990 ). 2. Covariates other than those included in our study may be more important in explaining ARC variation. We did not evaluate some potentially important predictors of cognitive decline, e.g., Apo E gene (Holmes et al., 1996; Kurz et al., 1996) , aphasia (Becker et al., 1988; Goldblum et al., 1994; Kurz et al., 1996; Mortimer et al., 1992; Yesavage et al., 1993) , and extrapyramidal signs (Corey-Bloom et al., 1993; Miller et al., 1991) , because they were not included in most of the studies. 3. Measurement error in coding the covariates or potential overestimating of the S D of ARC may have hidden the effects. However, we evaluated each continuous covariate using both its actual and categorical value in the regression models. The results did not differ significantly. Similarly, the source of ARC/SD estimates for individual studies was not related to the ARC. When the ARC was used as a dependent variable, no covariate was statistically significant. However, when ES was used as a more reliable and standardized outcome measure, two significant predictors, minimum MMSE at baseline and number of assessments, were found. These differences may have such a methodological implication that future studies should make more effort to improve the accuracy or reliability of ARC measurement before the true effect of any predictor of ARC can be determined. Although meta-analysis is a good method to synthesize research findings across studies, it cannot eliminate the methodological flaws of the original measurements. This review and meta-analysis has limitations. First, we may have missed some relevant studies that were unpublished, published in languages other than in English, or excluded based on abstracts only. However, our rigorous search strategy and cross-checking procedure make it unlikely that we missed important papers. Second, our evaluation of study methodology and population characteristics was selective: We focused on some predictors while neglecting others. However, the frequency of the predictors being evaluated across the studies probably reflected their recognized importance in planning a natural history study in an AD population, regardless of the particular interests of the researchers. Finally, our 243 study focused on the MMSE, which has been criticized for its inability to detect change in severely demented patients or to depict potential nonlinearity of the AD course (Morris et al., 1993; Tombaugh & McIntyre, 1992) . Development of measures that can describe the full course of AD deterioration has been suggested (Cole & Dastoor, 1996; Galasko et al., 1991) . Nevertheless, the MMSE performs well in patients with mild to moderate dementia, who are the target of most predictor and intervention studies. The MMSE is also the most widely used instrument in both clinical and research settings. A good understanding of the advantages and disadvantages of the MMSE in measuring the ARC of AD patients would serve as a starting point in understanding the usefulness of other instruments.
To conclude, great variation of ARC estimates existing across studies cannot be explained with the study or population characteristics we evaluated. Such unexplained ARC variability warrants further effort to improve the reliability and precision of ARC measurement. Stratum-specific ARC by baseline MMSE scores may be useful to serve this purpose. Given the potential limitations of this meta-analysis and of the MMSE, our combined ARC estimate may be most applicable to the course of mild or moderate AD during the first 1 or 2 years following the initial examination. However, we acknowledge that even though two patients may have the same ARC on MMSE scores, the content of their decline may differ dramatically. Finally, our combined estimate of ARC is based solely on MMSE data. Its relevance for other cognitive or function tests needs to be examined in both clinical and research settings.
